Your browser doesn't support javascript.
loading
Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency.
Zawerton, Ash; Mignot, Cyril; Sigafoos, Ashley; Blackburn, Patrick R; Haseeb, Abdul; McWalter, Kirsty; Ichikawa, Shoji; Nava, Caroline; Keren, Boris; Charles, Perrine; Marey, Isabelle; Tabet, Anne-Claude; Levy, Jonathan; Perrin, Laurence; Hartmann, Andreas; Lesca, Gaetan; Schluth-Bolard, Caroline; Monin, Pauline; Dupuis-Girod, Sophie; Guillen Sacoto, Maria J; Schnur, Rhonda E; Zhu, Zehua; Poisson, Alice; El Chehadeh, Salima; Alembik, Yves; Bruel, Ange-Line; Lehalle, Daphné; Nambot, Sophie; Moutton, Sébastien; Odent, Sylvie; Jaillard, Sylvie; Dubourg, Christèle; Hilhorst-Hofstee, Yvonne; Barbaro-Dieber, Tina; Ortega, Lucia; Bhoj, Elizabeth J; Masser-Frye, Diane; Bird, Lynne M; Lindstrom, Kristin; Ramsey, Keri M; Narayanan, Vinodh; Fassi, Emily; Willing, Marcia; Cole, Trevor; Salter, Claire G; Akilapa, Rhoda; Vandersteen, Anthony; Canham, Natalie; Rump, Patrick; Gerkes, Erica H.
Afiliação
  • Zawerton A; Department of Cellular & Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.
  • Mignot C; INSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.
  • Sigafoos A; AP-HP, Hôpital Pitié-Salpêtrière, Département de Génétique et de Cytogénétique; Centre de Référence Déficiences Intellectuelles de Causes Rares, GRC UPMC « Déficience Intellectuelle et Autisme ¼, Paris, France.
  • Blackburn PR; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
  • Haseeb A; Center for Individualized Medicine, Department of Health Science Research, and Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • McWalter K; Department of Surgery, Division of Orthopaedic Surgery, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Ichikawa S; GeneDx, Gaithersburg, MD, USA.
  • Nava C; Department of Clinical Diagnostics, Ambry Genetics, Aliso Viejo, CA, USA.
  • Keren B; INSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.
  • Charles P; AP-HP, Hôpital Pitié-Salpêtrière, Département de Génétique et de Cytogénétique; Centre de Référence Déficiences Intellectuelles de Causes Rares, GRC UPMC « Déficience Intellectuelle et Autisme ¼, Paris, France.
  • Marey I; INSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.
  • Tabet AC; AP-HP, Hôpital Pitié-Salpêtrière, Département de Génétique et de Cytogénétique; Centre de Référence Déficiences Intellectuelles de Causes Rares, GRC UPMC « Déficience Intellectuelle et Autisme ¼, Paris, France.
  • Levy J; AP-HP, Hôpital Pitié-Salpêtrière, Département de Génétique et de Cytogénétique; Centre de Référence Déficiences Intellectuelles de Causes Rares, GRC UPMC « Déficience Intellectuelle et Autisme ¼, Paris, France.
  • Perrin L; AP-HP, Hôpital Pitié-Salpêtrière, Département de Génétique et de Cytogénétique; Centre de Référence Déficiences Intellectuelles de Causes Rares, GRC UPMC « Déficience Intellectuelle et Autisme ¼, Paris, France.
  • Hartmann A; Genetics Department, Robert Debré Hospital, APHP, Paris, France.
  • Lesca G; Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France.
  • Schluth-Bolard C; Genetics Department, Robert Debré Hospital, APHP, Paris, France.
  • Monin P; Genetics Department, Robert Debré Hospital, APHP, Paris, France.
  • Dupuis-Girod S; INSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.
  • Guillen Sacoto MJ; APHP, Department of Neurology, Hôpital de la Pitié-Salpêtrière, Paris, France.
  • Schnur RE; Service de Génétique, Hospices Civils de Lyon - GHE, Lyon, France.
  • Zhu Z; CNRS UMR 5292, INSERM U1028, CNRL, and Université Claude Bernard Lyon 1, GHE, Lyon, France.
  • Poisson A; Service de Génétique, Hospices Civils de Lyon - GHE, Lyon, France.
  • El Chehadeh S; CNRS UMR 5292, INSERM U1028, CNRL, and Université Claude Bernard Lyon 1, GHE, Lyon, France.
  • Alembik Y; Service de Génétique, Hospices Civils de Lyon - GHE, Lyon, France.
  • Bruel AL; Service de Génétique, Hospices Civils de Lyon - GHE, Lyon, France.
  • Lehalle D; Centre de référence pour la maladie de Rendu-Osler, Bron, France.
  • Nambot S; GeneDx, Gaithersburg, MD, USA.
  • Moutton S; GeneDx, Gaithersburg, MD, USA.
  • Odent S; GeneDx, Gaithersburg, MD, USA.
  • Jaillard S; GénoPsy, Reference Center for Diagnosis and Management of Genetic Psychiatric Disorders, Centre Hospitalier le Vinatier and EDR-Psy Team (CNRS & Lyon 1 Claude Bernard University), Lyon, France.
  • Dubourg C; Département de Génétique Médicale, CHU de Hautepierre, Strasbourg, France.
  • Hilhorst-Hofstee Y; Département de Génétique Médicale, CHU de Hautepierre, Strasbourg, France.
  • Barbaro-Dieber T; INSERM 1231 LNC, Génétique des Anomalies du Développement, Université de Bourgogne-Franche Comté, Dijon, France.
  • Ortega L; FHU-TRANSLAD, Université de Bourgogne/CHU Dijon, Dijon, France.
  • Bhoj EJ; INSERM 1231 LNC, Génétique des Anomalies du Développement, Université de Bourgogne-Franche Comté, Dijon, France.
  • Masser-Frye D; Centre de Génétique et Centre de Référence Maladies Rares «Anomalies du Développement de l'Interrégion Est¼, Hôpital d'Enfants, CHU Dijon Bourgogne, Dijon, France.
  • Bird LM; INSERM 1231 LNC, Génétique des Anomalies du Développement, Université de Bourgogne-Franche Comté, Dijon, France.
  • Lindstrom K; Centre de Génétique et Centre de Référence Maladies Rares «Anomalies du Développement de l'Interrégion Est¼, Hôpital d'Enfants, CHU Dijon Bourgogne, Dijon, France.
  • Ramsey KM; INSERM 1231 LNC, Génétique des Anomalies du Développement, Université de Bourgogne-Franche Comté, Dijon, France.
  • Narayanan V; Centre de Génétique et Centre de Référence Maladies Rares «Anomalies du Développement de l'Interrégion Est¼, Hôpital d'Enfants, CHU Dijon Bourgogne, Dijon, France.
  • Fassi E; CHU de Rennes, service de génétique clinique, Rennes, France.
  • Willing M; Univ Rennes, CNRS, IGDR, UMR 6290, Rennes, France.
  • Cole T; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.
  • Salter CG; Univ Rennes, CNRS, IGDR, UMR 6290, Rennes, France.
  • Akilapa R; Service de Génétique Moléculaire et Génomique, CHU, Rennes, France.
  • Vandersteen A; Department of Clinical Genetics, Leiden University Medical Center, Leiden, Netherlands.
  • Canham N; Cook Childrens Medical Center, Fort Worth, TX, USA.
  • Rump P; Cook Childrens Medical Center, Fort Worth, TX, USA.
  • Gerkes EH; Department of Clinical Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Genet Med ; 22(3): 524-537, 2020 03.
Article em En | MEDLINE | ID: mdl-31578471
ABSTRACT

PURPOSE:

Lamb-Shaffer syndrome (LAMSHF) is a neurodevelopmental disorder described in just over two dozen patients with heterozygous genetic alterations involving SOX5, a gene encoding a transcription factor regulating cell fate and differentiation in neurogenesis and other discrete developmental processes. The genetic alterations described so far are mainly microdeletions. The present study was aimed at increasing our understanding of LAMSHF, its clinical and genetic spectrum, and the pathophysiological mechanisms involved.

METHODS:

Clinical and genetic data were collected through GeneMatcher and clinical or genetic networks for 41 novel patients harboring various types ofSOX5 alterations. Functional consequences of selected substitutions were investigated.

RESULTS:

Microdeletions and truncating variants occurred throughout SOX5. In contrast, most missense variants clustered in the pivotal SOX-specific high-mobility-group domain. The latter variants prevented SOX5 from binding DNA and promoting transactivation in vitro, whereas missense variants located outside the high-mobility-group domain did not. Clinical manifestations and severity varied among patients. No clear genotype-phenotype correlations were found, except that missense variants outside the high-mobility-group domain were generally better tolerated.

CONCLUSIONS:

This study extends the clinical and genetic spectrum associated with LAMSHF and consolidates evidence that SOX5 haploinsufficiency leads to variable degrees of intellectual disability, language delay, and other clinical features.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas de Ligação a DNA / Fatores de Transcrição SOXD / Transtornos do Neurodesenvolvimento / Deficiência Intelectual Tipo de estudo: Diagnostic_studies Limite: Adolescent / Adult / Animals / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas de Ligação a DNA / Fatores de Transcrição SOXD / Transtornos do Neurodesenvolvimento / Deficiência Intelectual Tipo de estudo: Diagnostic_studies Limite: Adolescent / Adult / Animals / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article